--Data presented at the American College of Cardiology Annual Scientific Session show that the reduction of bleeding with abelacimab compared…
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr…
NIJMEGEN, The Netherlands, March 26, 2025 (GLOBE NEWSWIRE) -- Pleco Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for difficult-to-treat…
Demonstrated substantial and statistically significant improvement in ADHD symptoms as measured by the AISRS total score compared to placebo (p=0.039,…
March 20, 2025 17:35 ET | Source: vTv Therapeutics Inc. Clinical hold lifted for late stage cadisegliatin program for diabetes…
March 19, 2025 04:00 ET | Source: Oxford BioTherapeutics Collaboration leverages OBT’s proprietary OGAP®-Verify discovery platform and Roche’s drug development…
FDA has granted CLPH-511 Fast Track Designation for the treatment of acute hemorrhage as an alternative to conventional platelets when…
March 17, 2025 09:25 ET | Source: Capricor Therapeutics --Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in…
Skyhawk presents today on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease to members of the Huntington's…
Meet with Indaptus Therapeutics’ CEO Jeffrey MecklerRegister at INDP-KEYS.TribePublic.com NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc.…
